A Phase 4 interventional study of non-invasive positive airway pressure and Methylprednisolone Hemisuccinate in Sudden Hearing Loss and Obstructive Sleep Apnea, sponsored by Beijing Tsinghua Chang Gung Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2019-12-10.
Sponsored by Beijing Tsinghua Chang Gung Hospital · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Hearing Loss, Sudden with a site in China — 11 open to participants now, 11 under way, 1 of them phase 3. Hearing Loss, Sudden · China.
Among the 18 studies in Hearing Loss, Sudden with a site in China, this one is the 7th largest by planned enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2019, is the only one in phase 4, reaches primary completion later than 1 of the 10 other live ones, and was the 4th registered.
66 studies on the registry are indexed under Hearing Loss, Sudden; 25 are open to participants now.
Browse Hearing Loss, Sudden studies →11 of the 18 studies in Hearing Loss, Sudden with a site in China are open now. Recruiting first, the newest first:
Eye & ENT Hospital of Fudan University · Sites in China
Ages 18–70
Guangdong Provincial People's Hospital · Sites in China
Ages 18–60
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18–60
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–65 · Healthy volunteers
Eye & ENT Hospital of Fudan University · Sites in China
Ages 12–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 10 Hearing Loss, Sudden studies recruiting now, 3 (30%) set no upper age limit and 5 (50%) stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 3 1 · Phase 4 1
First in 2019; this study’s year is marked. 3 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 102 is above the median of 72 across 49 interventional studies indexed under Hearing Loss, Sudden.
Median enrollment 90 across the 15 interventional studies, 90 across the 3 observational. Of the 1 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 18 have an industry lead sponsor. The 10 most frequent:
Beijing Tsinghua Chang Gung Hospital is the lead sponsor of 114 studies on the registry; 61 are open to participants now.
Beijing Tsinghua Chang Gung Hospital has 1 study filed under Hearing Loss, Sudden — fewer than ten, so there is no comparison to draw.
2 of the studies in Hearing Loss, Sudden with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07134075Eye & ENT Hospital of Fudan UniversityIntracochlear Injection of Glucocorticoid | 2027-08-01 |
| NCT07505667Guangdong Provincial People's HospitalYiyuancong for the Treatment of Sudden Sensorineural Hearing Loss | 2027-11-15 |
Add all 2 to your calendar (.ics) → With an account.
Among the 18 studies in Hearing Loss, Sudden with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical randomized controlled study is to explore the effect of positive airway pressure(PAP) on patients in Beijing Tsinghua Changgung Hospital diagnosed with both idiopathic sudden sensorineural hearing loss comorbided(ISSHL) and obstructive sleep apnea(OSA) between Dec. 2019 to Dec. 2029.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
patients treated by both PAP and medication
Device: non-invasive positive airway pressure · Drug: Methylprednisolone Hemisuccinate · Drug: Ginaton
patients treated by medication only
Drug: Methylprednisolone Hemisuccinate · Drug: Ginaton
non-invasive positive airway pressure is the first-line treatment for obstructive sleep apnea
Methylprednisolone is the first-line treatment of idiopathic sudden sensorineural hearing loss
Also known as: Methylprednisolone, MP
ginnaton is ginkgo biloba extract
Also known as: Ginkgo biloba extract,GBE
hearing threshold
the recovery of hearing threshold which will be measured by pure tone audiometry
Time frame: 3 months after onset of ISSHL
Started Nov 2019 (actual). Primary completion is estimated for Dec 2024, 61 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Beijing Tsinghua Chang Gung Hospital →